- Home
- TBBK vs BEAM Comparison
TBBK vs BEAM Comparison
Compare TBBK & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBBK
- BEAM
- Stock Information
- Founded
- TBBK 1999
- BEAM 2017
- Country
- TBBK United States
- BEAM United States
- Employees
- TBBK N/A
- BEAM N/A
- Industry
- TBBK Major Banks
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TBBK Finance
- BEAM Health Care
- Exchange
- TBBK Nasdaq
- BEAM Nasdaq
- Market Cap
- TBBK 2.6B
- BEAM 2.3B
- IPO Year
- TBBK 2004
- BEAM 2020
- Fundamental
- Price
- TBBK $56.13
- BEAM $30.43
- Analyst Decision
- TBBK Buy
- BEAM Buy
- Analyst Count
- TBBK 3
- BEAM 10
- Target Price
- TBBK $67.67
- BEAM $48.75
- AVG Volume (30 Days)
- TBBK 535.7K
- BEAM 1.2M
- Earning Date
- TBBK 01-30-2025
- BEAM 03-04-2025
- Dividend Yield
- TBBK N/A
- BEAM N/A
- EPS Growth
- TBBK 22.92
- BEAM N/A
- EPS
- TBBK 4.29
- BEAM N/A
- Revenue
- TBBK $495,381,000.00
- BEAM $349,643,000.00
- Revenue This Year
- TBBK N/A
- BEAM N/A
- Revenue Next Year
- TBBK $8.21
- BEAM $14.62
- P/E Ratio
- TBBK $13.59
- BEAM N/A
- Revenue Growth
- TBBK 10.62
- BEAM 328.73
- 52 Week Low
- TBBK $29.92
- BEAM $20.84
- 52 Week High
- TBBK $65.84
- BEAM $49.50
- Technical
- Relative Strength Index (RSI)
- TBBK 41.30
- BEAM 57.12
- Support Level
- TBBK $59.57
- BEAM $25.35
- Resistance Level
- TBBK $62.56
- BEAM $35.25
- Average True Range (ATR)
- TBBK 2.27
- BEAM 2.10
- MACD
- TBBK -0.62
- BEAM 0.56
- Stochastic Oscillator
- TBBK 2.71
- BEAM 55.88
About TBBK The Bancorp Inc
The Bancorp Inc is a financial holding company, through its subsidiary it is engaged in specialty lending namely securities-backed lines of credit, vehicle fleet and another equipment leasing, Small Business Administration lending, insurance policy cash value-backed lines of credit and commercial mortgage-backed loans, generated for sale into commercial mortgage-backed securities markets through securitizations. The company deposits and non-interest income are generated in the payments business which consists of issuing, acquiring, and automated clearing house accounts.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.